Tepmetko (tepotinib)

pCPA File Number: 21997

Negotiation Status:

Concluded with an LOI

Indication(s):

For the treatment of adult patients with locally advanced unresectable metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations

Sponsor/Manufacturer:

EMD Serono Canada, a division of EMD Inc.

CADTH Project Number:

PC0255

pCPA Engagement Letter Issued:

2023-03-09

Negotiation Process Concluded:

2023-06-22